Vor Biopharma enters into $125M at-the-market equity sales agreement with Stifel

Vor Biopharma Inc.

Agreement with Stifel for up to $125M of common stock sales in at-the-market offerings.
Stifel will receive a commission of 3.0% of gross sales proceeds from shares sold.
Replaces prior ATM agreement with Jefferies LLC, which was terminated on Dec 22, 2022.
Company has no obligation to sell shares; sales are at its sole discretion.
Prospectus supplement filed under existing Form S-3 registration statement (333-263541).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vor Biopharma Inc. entered into At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at up to $125.0 million (effective 2022-12-23).

Action: entry
Agreement: atm program
Counterparty: Stifel, Nicolaus & Company, Incorporated
Value: up to $125.0 million
Effective: 2022-12-23

Exact text from the filing

On December 23, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an At-the-Market Equity Offering Sales Agreement (the “ Agreement ”) with Stifel, Nicolaus & Company, Incorporated (“ Stifel ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), having an aggregate offering price of up to $125.0 million after the date of the Agreement through Stifel as its sales agent.

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-311777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.